Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | TACR1 | P25103 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | AGXT | P21549 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL715051 | 0.81 | TSHR (0.52) | TSHRTACR1ALDH1A1MEN1KMT2A | |
| SCHEMBL711818 | 0.79 | TSHR (0.48) | TSHRTACR1ALDH1A1MEN1KMT2A | |
| SCHEMBL4654483 | 0.79 | TSHR (0.48) | TSHRTACR1MEN1KMT2ANPSR1 | |
| SCHEMBL10371092 | 0.76 | TSHR (0.54) | TSHRTACR1ALDH1A1IDO1TAAR1 | |
| SCHEMBL714091 | 0.75 | TSHR (0.48) | TSHRTACR1ALDH1A1MEN1KMT2A | |
| SCHEMBL17611895 | 0.75 | TACR1 (0.44) | TSHRTACR1MEN1KMT2ANPSR1 | |
| SCHEMBL27674725 | 0.74 | TSHR (0.47) | TSHRTACR1MEN1KMT2ANPSR1 | |
| SCHEMBL754280 | 0.73 | TSHR (0.50) | TSHRTACR1ALDH1A1IDO1TAAR1 | |
| SCHEMBL16946080 | 0.72 | KMT2A (0.41) | TSHRTACR1ALDH1A1MEN1KMT2A | |
| SCHEMBL416619 | 0.72 | TACR1 (0.42) | TSHRTACR1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2138179-A1 | Use of cytidine derivatives for the treatment of leukaemia | Shire Canada Inc. (CA) | 2009-12-30 | — | — | EP | disclosed |
| EP-1165096-B1 | USE OF CYTIDINE DERIVATIVES FOR THE TREATMENT OF LEUKAEMIA | SHIRE CANADA INC (CA) | 2009-09-09 | — | — | EP | disclosed |
| CN-1297281-C | Method for treatment of leukaemia | HILA BIOCHEM PHARMA INC (CA) | 2007-01-31 | — | — | CN | disclosed |
| US-6964968-B2 | Method for the treatment or prevention of viral infection using nucleoside analogues | SHIRE BIOCHEM, INC. (CA) | 2005-11-15 | — | — | US | disclosed |
| US-20050101571-A1 | Methods of treating cancer using a combination of drugs | JOLIVET JACQUES (CA) | 2005-05-12 | — | — | US | disclosed |
| US-20040192654-A1 | Methods of treating leukemia | BIOCHEM PHARMA INC. (CA) | 2004-09-30 | — | — | US | disclosed |
| EP-1214074-B1 | DIOXOLANE NUCLEOSIDE ANALOGS FOR THE TREATMENT OR PREVENTION OF VIRAL INFECTION | SHIRE BIOCHEM INC (CA) | 2004-06-16 | — | — | EP | disclosed |
| US-6747036-B2 | USE OF NUCLEOSIDE ANALOGUES (CYTOSINE OR 5-FLUOROCYTOSINE CONTAINING COMPOUND) USEFUL FOR ACUTE OR CHRONIC MYELOGENOUS LEUKEMIA | BIOCHEM PHARMA INC. (CA) | 2004-06-08 | — | — | US | disclosed |
| US-20040014757-A1 | Method for the treatment or prevention of viral infection using nucleoside analogues | BIOCHEM PHARMA INC. (CA) | 2004-01-22 | — | — | US | disclosed |
| EP-1372658-A2 | METHODS OF TREATING CANCER USING CYPLASTIN COMBINED WITH A DIOXOLANE NUCLEOSIDE SUCH AS TROXACITABINE | Shire Biochem Inc. (CA) | 2004-01-02 | — | — | EP | disclosed |
| US-20030027799-A1 | Methods of treating cancer using a combination of drugs | SHIRE BIOCHEM INC. (CA) | 2003-02-06 | — | — | US | disclosed |
| WO-2002078678-A2 | METHODS OF TREATING CANCER USING CYPLASTIN COMBINED WITH A DIOXOLANE NUCLEOSIDE SUCH AS TROXACITABINE | SHIRE BIOCHEM INC. (CA) | 2002-10-10 | — | — | WO | disclosed |
| US-20020107225-A1 | Methods of treating leukemia | BIOCHEM PHARMA INC. (CA) | 2002-08-08 | — | — | US | disclosed |
| US-20020058670-A1 | Method and compositions for the synthesis of dioxolane nucleosides with beta-configuration | BIOCHEM PHARMA INC. | 2002-05-16 | — | — | US | disclosed |
| CN-1345242-A | Method for treating leukemia | HILA BIOCHEM PHARMA INC (CA) | 2002-04-17 | — | — | CN | disclosed |
| EP-0970074-B1 | METHOD AND COMPOSITIONS FOR THE SYNTHESIS OF DIOXOLANE NUCLEOSIDES WITH BETA-CONFIGURATION | SHIRE BIOCHEM INC (CA) | 2002-03-20 | — | — | EP | disclosed |
| CN-1080263-C | Method and compositions for the synthesis of dioxolane nucleosides with 'beta'-configuration | IAF BIOCHEM INT (CA) | 2002-03-06 | — | — | CN | disclosed |
| US-6069250-A | STEREOSELECTIVE SYNTHESIS OF THE BETA (CIS) ISOMER BY GLYCOSYLATING THE BASE WITH A 2-PROTECTED HYDROXYL-4-HALO-1,3-DIOXOLANE AT A TEMPERATURE OF-10 DEGREES C.; KINETICS | BIOCHEM PHARMA INC. (CA) | 2000-05-30 | — | — | US | disclosed |
| US-5922867-A | GLYCOSYLATING THE NUCLEOSIDE BASE WITH AN CHEMICAL INTERMEDIATE BELOW A TEMPERATURE OF ABOUT-10.DEGREE. C. | BIOCHEM PHARMA INC. (CA) | 1999-07-13 | — | — | US | disclosed |
| CN-1208414-A | Method and compositions for the synthesis of dioxolane nucleosides with 'beta'-configuration | IAF BIOCHEM INT (CA) | 1999-02-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027799-A1 | Methods of treating cancer using a combination of drugs | TYMP, DPYD, MTHFD1 | TSHR 3049/4885TACR1 1376/4885ALDH1A1 107/4885 |
| US-20040014757-A1 | Method for the treatment or prevention of viral infection using nucleoside analogues | TREH, HPRT1, TYMP | TSHR 4451/4885TACR1 2419/4885ALDH1A1 3710/4885 |
| US-20020107225-A1 | Methods of treating leukemia | MCL1, HCCS, BCL9 | TSHR 4262/4885TACR1 4195/4885ALDH1A1 108/4885 |
| US-20040192654-A1 | Methods of treating leukemia | MCL1, HCCS, BCL9 | TSHR 4188/4885TACR1 4187/4885ALDH1A1 103/4885 |
| US-20020058670-A1 | Method and compositions for the synthesis of dioxolane nucleosides with beta-configuration | DPYD, DHPS, DAD1 | TSHR 3713/4885TACR1 3668/4885ALDH1A1 497/4885 |
| US-20050101571-A1 | Methods of treating cancer using a combination of drugs | TYMP, DPYD, NTPCR | TSHR 2627/4885TACR1 1087/4885ALDH1A1 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.